|
Acephalic spermatozoa
|
0.110 |
GeneticVariation
|
disease |
BEFREE |
Therefore, we speculate that the presence of rare sequence variants within TSGA10 may be associated with acephalic spermatozoa in humans.
|
28905369 |
2018 |
|
Acephalic spermatozoa
|
0.110 |
Biomarker
|
disease |
HPO |
|
|
|
|
Intelligence
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
A combined analysis of genetically correlated traits identifies 187 loci and a role for neurogenesis and myelination in intelligence.
|
29326435 |
2019 |
|
Serum albumin measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
A genome-wide assessment of variability in human serum metabolism.
|
23281178 |
2013 |
|
Infertility
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Therefore, this study showed that overexpression of TSGA10, as a tumor suppressor gene, in endothelial cells resulted in decreased proliferation, migration and therefore, angiogenic activity of HUVECs.
|
31704243 |
2020 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
BACKGROUND Testis-specific gene antigen 10 (TSGA10) is a tumor suppressor in several types of human malignancy.
|
31310599 |
2019 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Altogether, the current study showed that TSGA10 could be considered as a tumor suppressor in AML patients.
|
30638859 |
2019 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
RESULTS Upregulation of TSGA10 expression in tissues from patients with bladder cancer was compared with normal adjacent bladder tissue and was significantly correlated with gender, metastasis, lymphovascular invasion, and tumor stage in bladder cancer.
|
31310599 |
2019 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Although it has been shown that TSGA10 messenger RNA (mRNA) is mainly expressed in testis and some tumors, the transcription pattern and regulatory mechanisms of this gene remain largely unknown.
|
28739310 |
2017 |
|
Malignant Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
In this study, we found that down-regulation of TSGA10 was associated with increased malignancy and clinical features of esophageal squamous cell carcinomas (ESCCs).
|
24294352 |
2013 |
|
Malignant Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
TSGA10 expression has been observed in a wide spectrum of cancers but not in hematopoietic neoplasm.
|
16406020 |
2006 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Serological analysis revealed that 3 out of 346 patients with various types of cancer possessed antibody against recombinant TSGA10 protein.
|
15107545 |
2004 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
BACKGROUND Testis-specific gene antigen 10 (TSGA10) is a tumor suppressor in several types of human malignancy.
|
31310599 |
2019 |
|
Primary malignant neoplasm
|
0.030 |
AlteredExpression
|
group |
BEFREE |
In this study, we found that down-regulation of TSGA10 was associated with increased malignancy and clinical features of esophageal squamous cell carcinomas (ESCCs).
|
24294352 |
2013 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
Serological analysis revealed that 3 out of 346 patients with various types of cancer possessed antibody against recombinant TSGA10 protein.
|
15107545 |
2004 |
|
Malignant neoplasm of urinary bladder
|
0.020 |
Biomarker
|
disease |
BEFREE |
CONCLUSIONS These findings support that TSGA10 deserves further study as a potential novel prognostic biomarker in bladder cancer.
|
31310599 |
2019 |
|
Bladder Neoplasm
|
0.020 |
Biomarker
|
disease |
BEFREE |
CONCLUSIONS These findings support that TSGA10 deserves further study as a potential novel prognostic biomarker in bladder cancer.
|
31310599 |
2019 |
|
Malignant neoplasm of urinary bladder
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
In malignant tissues, TSGA10 was over-expressed in 4 of 20 hepatocellular carcinomas (HCC), 1 of 20 colon cancers, 7 of 20 ovarian cancers, 3 of 20 prostate cancers, 1 of 21 malignant melanomas, and 8 of 21 bladder cancers.
|
15107545 |
2004 |
|
Bladder Neoplasm
|
0.020 |
AlteredExpression
|
disease |
LHGDN |
Over-expression of the testis-specific gene TSGA10 in cancers and its immunogenicity.
|
15107545 |
2004 |
|
Leukemia, Myelocytic, Acute
|
0.010 |
Biomarker
|
disease |
BEFREE |
Altogether, the current study showed that TSGA10 could be considered as a tumor suppressor in AML patients.
|
30638859 |
2019 |
|
Carcinoma of bladder
|
0.010 |
Biomarker
|
disease |
BEFREE |
CONCLUSIONS These findings support that TSGA10 deserves further study as a potential novel prognostic biomarker in bladder cancer.
|
31310599 |
2019 |
|
Nasopharyngeal carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Metastasis-associated miR-23a from nasopharyngeal carcinoma-derived exosomes mediates angiogenesis by repressing a novel target gene TSGA10.
|
29520105 |
2018 |
|
Malignant neoplasm of breast
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We found that TSGA10 tends to express variants with shorter 5'UTR and fewer uORF elements in breast cancer tissues.
|
28739310 |
2017 |
|
Malignant neoplasm of testis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Testis specific gene antigen 10 (TSGA10) is a cancer testis antigen involved in the process of spermatogenesis.
|
28739310 |
2017 |